What is Mayflower Bioscience?
Headquartered in St. Louis, Missouri, Mayflower Bioscience operates as a critical node in the drug discovery and molecular biology supply chain. By providing a curated portfolio of high-quality antibodies, bioassays, and specialized testing products, the company serves as an essential partner for research institutions and pharmaceutical developers across North America. Their market position is defined by a commitment to technical excellence and localized customer support, ensuring that researchers in the US and Canada have reliable access to the tools necessary for complex scientific inquiry. The company's ability to bridge the gap between innovative product sourcing and end-user application has established it as a reliable entity in the life sciences ecosystem.
How much funding has Mayflower Bioscience raised?
Mayflower Bioscience has raised a total of $732K across 1 funding round:
Debt
$732K
Debt (2024): $732K with participation from St Louis Bank
Key Investors in Mayflower Bioscience
St Louis Bank
A regional financial institution providing commercial banking services and debt financing solutions to support the growth of local enterprises.
What's next for Mayflower Bioscience?
The deployment of this recent capital is expected to catalyze Mayflower Bioscience's expansion into new research verticals and enhance its existing product distribution infrastructure. As the firm transitions into this next phase of growth, the focus will likely shift toward scaling its bioassay offerings and deepening its penetration into the drug discovery market. By maintaining a lean operational model supported by strategic debt financing, the company is well-positioned to navigate the complexities of the biotech supply chain while continuing to deliver value to its diverse client base. Future initiatives will likely prioritize the integration of advanced molecular biology technologies to meet the evolving demands of the global research community.
See full Mayflower Bioscience company page
